Iradimed Co Stock Total Debt
| IRMD Stock | USD 52.75 0.64 1.20% |
Iradimed Co fundamentals help investors to digest information that contributes to Iradimed's financial success or failures. It also enables traders to predict the movement of Iradimed Stock. The fundamental analysis module provides a way to measure Iradimed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Iradimed stock.
The current year's Total Debt To Capitalization is expected to grow to 0.06. Iradimed | Total Debt |
Iradimed Co Company Total Debt Analysis
Iradimed's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Iradimed Total Debt | 2.04 M |
Most of Iradimed's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Iradimed Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Iradimed Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Iradimed is extremely important. It helps to project a fair market value of Iradimed Stock properly, considering its historical fundamentals such as Total Debt. Since Iradimed's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Iradimed's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Iradimed's interrelated accounts and indicators.
Click cells to compare fundamentals
Iradimed Total Debt Historical Pattern
Today, most investors in Iradimed Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Iradimed's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Iradimed total debt as a starting point in their analysis.
Iradimed Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Iradimed Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Iradimed Co has a Total Debt of 2.04 M. This is 99.93% lower than that of the Health Care Equipment & Supplies sector and 99.88% lower than that of the Health Care industry. The total debt for all United States stocks is 99.96% higher than that of the company.
Iradimed Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Iradimed's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Iradimed could also be used in its relative valuation, which is a method of valuing Iradimed by comparing valuation metrics of similar companies.Iradimed is currently under evaluation in total debt category among its peers.
Iradimed Current Valuation Drivers
We derive many important indicators used in calculating different scores of Iradimed from analyzing Iradimed's financial statements. These drivers represent accounts that assess Iradimed's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Iradimed's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 263.8M | 276.4M | 570.5M | 355.4M | 598.3M | 628.2M | |
| Enterprise Value | 223.3M | 229.1M | 511.0M | 299.6M | 550.5M | 578.1M |
Iradimed ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Iradimed's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Iradimed's managers, analysts, and investors.Environmental | Governance | Social |
Iradimed Institutional Holders
Institutional Holdings refers to the ownership stake in Iradimed that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Iradimed's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Iradimed's value.| Shares | Acadian Asset Management Llc | 2024-06-30 | 160.4 K | Northern Trust Corp | 2024-09-30 | 133.3 K | Hightower Advisors, Llc | 2024-06-30 | 103 K | Soleus Capital Management, L.p. | 2024-06-30 | 102.1 K | Millennium Management Llc | 2024-06-30 | 83.1 K | Goldman Sachs Group Inc | 2024-06-30 | 79 K | Rice Hall James & Associates, Llc | 71.6 K | Teacher Retirement System Of Texas | 2024-09-30 | 70.1 K | Charles Schwab Investment Management Inc | 2024-09-30 | 66.6 K | Nine Ten Capital Management Llc | 2024-09-30 | 905.9 K | Blackrock Inc | 2024-06-30 | 818.3 K |
Iradimed Fundamentals
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.26 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 627.59 M | ||||
| Shares Outstanding | 12.67 M | ||||
| Shares Owned By Insiders | 36.97 % | ||||
| Shares Owned By Institutions | 57.03 % | ||||
| Number Of Shares Shorted | 85.85 K | ||||
| Price To Earning | 28.70 X | ||||
| Price To Book | 8.14 X | ||||
| Price To Sales | 9.52 X | ||||
| Revenue | 65.56 M | ||||
| Gross Profit | 41.28 M | ||||
| EBITDA | 20.04 M | ||||
| Net Income | 17.19 M | ||||
| Cash And Equivalents | 55.59 M | ||||
| Cash Per Share | 4.42 X | ||||
| Total Debt | 2.04 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 12.83 X | ||||
| Book Value Per Share | 6.58 X | ||||
| Cash Flow From Operations | 13.47 M | ||||
| Short Ratio | 2.49 X | ||||
| Earnings Per Share | 1.46 X | ||||
| Price To Earnings To Growth | 4.46 X | ||||
| Target Price | 60.0 | ||||
| Number Of Employees | 148 | ||||
| Beta | 0.8 | ||||
| Market Capitalization | 679.04 M | ||||
| Total Asset | 92.16 M | ||||
| Retained Earnings | 43.26 M | ||||
| Working Capital | 59.67 M | ||||
| Current Asset | 33.95 M | ||||
| Current Liabilities | 2.89 M | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 92.16 M | ||||
| Last Dividend Paid | 0.45 |
About Iradimed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Iradimed Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iradimed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iradimed Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:Check out Iradimed Piotroski F Score and Iradimed Altman Z Score analysis. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0) | Dividend Share 0.45 | Earnings Share 1.46 | Revenue Per Share 5.635 | Quarterly Revenue Growth 0.11 |
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.